Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We've got a very well-defined criteria of what we look for, like leading brands that define categories that are set up for long-term growth |
| We feel good about them and our ability to start to recover margin |
| Even in today's evolving marketplace, our diverse portfolio of leading healthcare brands provide a great starting point that supports predictable, long-term, top-line organic growth of 2% to 3% annually |
| and continued strength in our international segment, which more than offset the impact from the strategic exit of the private label business we've previously discussed |
| As expected, gross margin improved versus the prior year, enabling increased marketing reinvestment |
| Clearly, the international business has grown way above what we would expect it to be over the long-term |
| We are pleased with this improved EPS forecast that is driven by our proven business strategy and a well-positioned and diversified portfolio |
| So in summary, our strong Q3 performance built on a solid first half and these results continue to enable robust free cash flow that can drive incremental shareholder value from our proven business strategy |
| So obviously here we've had strong international segment |
| So we feel good about the long-term algorithm for the international business, which is growth at 5%-plus |
| TheraTears is well established as a leader in dry eye solutions |
| And this year, in particular, we're experiencing good growth really across the portfolio |
| So we don't talk about it much because we focus on Hydralyte a lot, and Hydralyte did have a really strong third quarter and has been continuing to grow for us, and we expect continued growth in the long-term |
| These help establish category leadership with both retailers and consumers that enables brand building and long-term growth |
| We are on pace to deliver excellent full year results and exceed the earnings outlook that we began the year with |
| Year-to-date, we also experienced solid high single-digit year-over-year growth in the e-commerce channel |
| So over the long-term, it's both good for our brands and the industry as consumers reminded of the importance of those trusted brands and quality product |
| For EPS, we now anticipate diluted EPS of approximately $4.33 for fiscal '24, thanks to our strong year-to-date results and the power of our cash flow |
| This level of growth is amplified by our industry-leading cash flows that accelerate this top-line growth into 6% to 8% organic EPS growth over the long-term |
| Equally important are strong free cash flow and resulting deleveraging creates additional optionality for capital deployment including M&A that can drive significant upside to this algorithm |
| We are very pleased with our Q3 performance that exceeded our sales and earnings expectations and added to our strong results earlier in the fiscal year |
| The results of our strategy is a winning franchise that continues to experience solid growth |
| After certain supply disruptions in fiscal '23, we've returned to growth of over 10% year-to-date and continue to grow in the mid-single-digit range over-time, thanks to these characteristics |
| And I think both in Chris' comments and mine today, it's a reminder that we continue to be very well positioned to create value for our shareholders with our cash flow and our lower level of leverage, whether it's continuing to invest in the business, M&A, delevering even lower over-time, stock buybacks |
| The international segment performed above our long-term expectations, thanks to strong performance across numerous brands and geographies |
| On the bottom line, EPS really helped by a more stable interest rate environment |
| International OTC segment revenues increased approximately 20% versus the prior year, with broad-based strength that included solid double-digit growth for the Hydralyte brand |
| EPS increased 2.2% in Q3 from the prior year, reflecting the benefit of our free cash flow and reducing debt in a more stable interest rate environment |
| Net sales were $283 million in the third quarter, up nearly 3% and ahead of our outlook |
| And Summer's Eve continues to see improving trends and both of those brands should be in a good position to begin growth for next year |
| Statement |
|---|
| This implies revenue for the full-year at the lower end of our original guidance, driven largely by unfavorable FX |
| Total company gross margin of 55.7% in the first nine months was down slightly versus prior year, owing to challenging comparisons in Q1 |
| Maybe if you could talk about the other categories? And then also I think you mentioned that non-core brands, you maybe saw some weakness there |
| And then in addition to that, right, there's some nuances in the eye care supply chain where periodic shutdowns as they do maintenance and other things can put a little bit of a pause in delivery for all the players in there |
| Business environment uncertainty remains heightened due to a variety of factors including high inflation, geopolitical events, and supply chain constraints, which have numerous potential impacts |
| Over-time, we would expect that the non-core and tail brands would decline |
| And we talked about that last year in the quarter ended December, where we had a little bit of a pause in supply |
| There's been some recalls |
| For Q3, pricing was a little bit less than half, right, as we start to lap continue through the year |
| And then just finally, I wanted to ask, we've been saying a lot about recalls of various eye drop products |
| We'll talk about in May, but there is certainly nothing structural that would prevent us from doing that |
| So I guess given there's been a lot of concerns just about cough and cold, I would just love to hear your expectations for Q4 for that category |
| And then when it comes to -- you look at the gross margin longer term, you're slowly recovering from levels five years ago or more |
| So I wouldn't say we're going to be more aggressive |
| Jon Andersen Let’s see anything going on from a channel perspective of note, strength in certain areas, softness in others |
| The big impact this year, Anthony, really has been the Women's Health business, which in total is about 20%-ish of sales |
| In general, we haven't seen any share loss or share shift as a result of consumers moving away from our products to lower priced or private label in particular |
| If you could just talk about the cost savings that you have put in place to help work gross margin back, given the inflationary pressures |
| But as you mentioned, the math takes the margin part of it a little while to catch-up |
| So never say never |
Please consider a small donation if you think this website provides you with relevant information